Cargando…

Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy

PURPOSE: Iron-based nanomaterials have recently been developed as excellent and potent Fenton reagents to reactive oxygen species (ROS) during chemodynamic therapy (CDT). The performance of the materials, however, can be impaired by the intrinsic antioxidant defense mechanism in organisms, such as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xiaodi, Pu, Xin, Wang, Jing, Yang, Linlin, Cui, Yunxia, Li, Lijuan, Sun, Xiao, Liu, Jichang, Bai, Jingfeng, Wang, Yudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487866/
https://www.ncbi.nlm.nih.gov/pubmed/34616150
http://dx.doi.org/10.2147/IJN.S329341
_version_ 1784578046278238208
author Gong, Xiaodi
Pu, Xin
Wang, Jing
Yang, Linlin
Cui, Yunxia
Li, Lijuan
Sun, Xiao
Liu, Jichang
Bai, Jingfeng
Wang, Yudong
author_facet Gong, Xiaodi
Pu, Xin
Wang, Jing
Yang, Linlin
Cui, Yunxia
Li, Lijuan
Sun, Xiao
Liu, Jichang
Bai, Jingfeng
Wang, Yudong
author_sort Gong, Xiaodi
collection PubMed
description PURPOSE: Iron-based nanomaterials have recently been developed as excellent and potent Fenton reagents to reactive oxygen species (ROS) during chemodynamic therapy (CDT). The performance of the materials, however, can be impaired by the intrinsic antioxidant defense mechanism in organisms, such as autophagy. METHODS: The nanoscale metal-organic frameworks (nMOFs), nMIL-100 (Fe), were exploited and characterized. Also, the Fenton-like catalytic characteristics, anti-endometrial cancer (EC) effects and potential mechanisms of nMIL-100 (Fe) nanoparticles were investigated in vitro. RESULTS: The synthesized nMIL-100 (Fe) nanocatalyst catalyzed hydroxyl radicals (·OH) production in the presence of hydrogen peroxide (H(2)O(2)) and simultaneously depleted intracellular glutathione (GSH). Combining with H(2)O(2), nMIL-100 (Fe) nanoparticles exhibited enhanced cytotoxicity for EC cells, especially for progesterone treatment-insensitive KLE cells, probably due to relatively lower expression of the catalase gene. The accumulated ·OH initiated PTEN induced putative kinase 1 (PINK1)/E3 ubiquitin-protein ligase Parkin-mediated cytoprotective mitophagy in turn to partially rescue ·OH-induced cell apoptosis. Furthermore, both pretreatments of EC cells with siRNA-mediated Parkin knockdown and Mdivi-1 (a mitophagy inhibitor) addition were sufficient to ensure nMIL-100 (Fe) synergizing with H(2)O(2)-induced oxidative damages. CONCLUSION: These results suggest that the degree of mitophagy should be taken into consideration to optimize therapeutic efficiency when developing ROS based-CDT for EC cancer therapies. Therefore, a nMIL-100 (Fe)-guided, elevated ROS and overwhelmed mitophagy-mediated therapeutic strategy may have greater promise for EC therapy compared with current treatment modalities.
format Online
Article
Text
id pubmed-8487866
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84878662021-10-05 Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy Gong, Xiaodi Pu, Xin Wang, Jing Yang, Linlin Cui, Yunxia Li, Lijuan Sun, Xiao Liu, Jichang Bai, Jingfeng Wang, Yudong Int J Nanomedicine Original Research PURPOSE: Iron-based nanomaterials have recently been developed as excellent and potent Fenton reagents to reactive oxygen species (ROS) during chemodynamic therapy (CDT). The performance of the materials, however, can be impaired by the intrinsic antioxidant defense mechanism in organisms, such as autophagy. METHODS: The nanoscale metal-organic frameworks (nMOFs), nMIL-100 (Fe), were exploited and characterized. Also, the Fenton-like catalytic characteristics, anti-endometrial cancer (EC) effects and potential mechanisms of nMIL-100 (Fe) nanoparticles were investigated in vitro. RESULTS: The synthesized nMIL-100 (Fe) nanocatalyst catalyzed hydroxyl radicals (·OH) production in the presence of hydrogen peroxide (H(2)O(2)) and simultaneously depleted intracellular glutathione (GSH). Combining with H(2)O(2), nMIL-100 (Fe) nanoparticles exhibited enhanced cytotoxicity for EC cells, especially for progesterone treatment-insensitive KLE cells, probably due to relatively lower expression of the catalase gene. The accumulated ·OH initiated PTEN induced putative kinase 1 (PINK1)/E3 ubiquitin-protein ligase Parkin-mediated cytoprotective mitophagy in turn to partially rescue ·OH-induced cell apoptosis. Furthermore, both pretreatments of EC cells with siRNA-mediated Parkin knockdown and Mdivi-1 (a mitophagy inhibitor) addition were sufficient to ensure nMIL-100 (Fe) synergizing with H(2)O(2)-induced oxidative damages. CONCLUSION: These results suggest that the degree of mitophagy should be taken into consideration to optimize therapeutic efficiency when developing ROS based-CDT for EC cancer therapies. Therefore, a nMIL-100 (Fe)-guided, elevated ROS and overwhelmed mitophagy-mediated therapeutic strategy may have greater promise for EC therapy compared with current treatment modalities. Dove 2021-09-29 /pmc/articles/PMC8487866/ /pubmed/34616150 http://dx.doi.org/10.2147/IJN.S329341 Text en © 2021 Gong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gong, Xiaodi
Pu, Xin
Wang, Jing
Yang, Linlin
Cui, Yunxia
Li, Lijuan
Sun, Xiao
Liu, Jichang
Bai, Jingfeng
Wang, Yudong
Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
title Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
title_full Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
title_fullStr Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
title_full_unstemmed Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
title_short Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
title_sort enhancing of nanocatalyst-driven chemodynaminc therapy for endometrial cancer cells through inhibition of pink1/parkin-mediated mitophagy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487866/
https://www.ncbi.nlm.nih.gov/pubmed/34616150
http://dx.doi.org/10.2147/IJN.S329341
work_keys_str_mv AT gongxiaodi enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT puxin enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT wangjing enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT yanglinlin enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT cuiyunxia enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT lilijuan enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT sunxiao enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT liujichang enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT baijingfeng enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy
AT wangyudong enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy